CORDIS
EU research results

CORDIS

English EN

FRAME - tumor genome-based personalized anti-cancer vaccines off-the-shelf

Project information

Grant agreement ID: 877768

  • Start date

    1 August 2019

  • End date

    31 January 2020

Funded under:

H2020-EU.3.

H2020-EU.2.3.

H2020-EU.2.1.

  • Overall budget:

    € 71 429

  • EU contribution

    € 50 000

Coordinated by:

FRAME PHARMACEUTICALS BV

Netherlands

Project description

English EN

Frame-shift mutation based anticancer vaccination

Immunotherapy shows impressive potential for cancer treatment. This approach involving the general activation of the immune system would benefit dramatically if combined with tumour-specific vaccination. This is now possible with technology enabling routine sequencing of the entire tumour DNA within two weeks. Frame Cancer Therapeutics has developed a new kind of personalised anticancer vaccine based on shared neoantigens induced by frameshift mutations. These sequences are not normally expressed, and are thus attacked by the immune system, enabling specific vaccines for different tumour types. The EU-funded project focuses on the development of specific sets of vaccines for cancers according to their shift-mutations, providing an effective and less-expensive approach compared to point-mutation based neoantigen vaccination.

Coordinator

FRAME PHARMACEUTICALS BV

Address

Science Park 106
1098 Xg Amsterdam

Netherlands

Activity type

Private for-profit entities (excluding Higher or Secondary Education Establishments)

EU Contribution

€ 50 000

Project information

Grant agreement ID: 877768

  • Start date

    1 August 2019

  • End date

    31 January 2020

Funded under:

H2020-EU.3.

H2020-EU.2.3.

H2020-EU.2.1.

  • Overall budget:

    € 71 429

  • EU contribution

    € 50 000

Coordinated by:

FRAME PHARMACEUTICALS BV

Netherlands